Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

1.

Peptides as Therapeutic Agents for Dengue Virus.

Chew MF, Poh KS, Poh CL.

Int J Med Sci. 2017 Oct 15;14(13):1342-1359. doi: 10.7150/ijms.21875. eCollection 2017. Review.

2.

Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections.

Zhang X, Jia R, Shen H, Wang M, Yin Z, Cheng A.

Viruses. 2017 Nov 13;9(11). pii: E338. doi: 10.3390/v9110338. Review.

3.

Structure-based pKa prediction provides a thermodynamic basis for the role of histidines in pH-induced conformational transitions in dengue virus.

Chaudhury S, Ripoll DR, Wallqvist A.

Biochem Biophys Rep. 2015 Oct 31;4:375-385. doi: 10.1016/j.bbrep.2015.10.014. eCollection 2015 Dec.

4.

Phage-Displayed Peptides Selected to Bind Envelope Glycoprotein Show Antiviral Activity against Dengue Virus Serotype 2.

de la Guardia C, Quijada M, Lleonart R.

Adv Virol. 2017;2017:1827341. doi: 10.1155/2017/1827341. Epub 2017 Sep 10.

5.

Characterization and epitope mapping of Dengue virus type 1 specific monoclonal antibodies.

Chen WH, Chou FP, Wang YK, Huang SC, Cheng CH, Wu TK.

Virol J. 2017 Oct 2;14(1):189. doi: 10.1186/s12985-017-0856-8.

6.

An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Urakami A, Ngwe Tun MM, Moi ML, Sakurai A, Ishikawa M, Kuno S, Ueno R, Morita K, Akahata W.

J Virol. 2017 Nov 14;91(23). pii: e01181-17. doi: 10.1128/JVI.01181-17. Print 2017 Dec 1.

PMID:
28956764
7.

A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential.

Wang J, Bardelli M, Espinosa DA, Pedotti M, Ng TS, Bianchi S, Simonelli L, Lim EXY, Foglierini M, Zatta F, Jaconi S, Beltramello M, Cameroni E, Fibriansah G, Shi J, Barca T, Pagani I, Rubio A, Broccoli V, Vicenzi E, Graham V, Pullan S, Dowall S, Hewson R, Jurt S, Zerbe O, Stettler K, Lanzavecchia A, Sallusto F, Cavalli A, Harris E, Lok SM, Varani L, Corti D.

Cell. 2017 Sep 21;171(1):229-241.e15. doi: 10.1016/j.cell.2017.09.002.

PMID:
28938115
8.

Dengue Virus Glycosylation: What Do We Know?

Yap SSL, Nguyen-Khuong T, Rudd PM, Alonso S.

Front Microbiol. 2017 Jul 25;8:1415. doi: 10.3389/fmicb.2017.01415. eCollection 2017. Review.

9.

Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.

Tsai WY, Lin HE, Wang WK.

Front Microbiol. 2017 Jul 20;8:1372. doi: 10.3389/fmicb.2017.01372. eCollection 2017. Review.

10.

A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses.

Yu Y, Deng YQ, Zou P, Wang Q, Dai Y, Yu F, Du L, Zhang NN, Tian M, Hao JN, Meng Y, Li Y, Zhou X, Fuk-Woo Chan J, Yuen KY, Qin CF, Jiang S, Lu L.

Nat Commun. 2017 Jul 25;8:15672. doi: 10.1038/ncomms15672.

11.

Structural Basis for CD4+ T Cell Epitope Dominance in Arbo-Flavivirus Envelope Proteins: A Meta-Analysis.

Landry SJ, Moss DL, Cui D, Ferrie RP, Fullerton ML, Wells EA, Yang L, Zhou N, Dougherty T, Mettu RR.

Viral Immunol. 2017 Sep;30(7):479-489. doi: 10.1089/vim.2017.0008. Epub 2017 Jun 14.

PMID:
28614011
12.

Assembly, maturation and three-dimensional helical structure of the teratogenic rubella virus.

Mangala Prasad V, Klose T, Rossmann MG.

PLoS Pathog. 2017 Jun 2;13(6):e1006377. doi: 10.1371/journal.ppat.1006377. eCollection 2017 Jun.

13.

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope.

Rouvinski A, Dejnirattisai W, Guardado-Calvo P, Vaney MC, Sharma A, Duquerroy S, Supasa P, Wongwiwat W, Haouz A, Barba-Spaeth G, Mongkolsapaya J, Rey FA, Screaton GR.

Nat Commun. 2017 May 23;8:15411. doi: 10.1038/ncomms15411.

14.

Pathogenesis and Inhibition of Flaviviruses from a Carbohydrate Perspective.

Kim SY, Li B, Linhardt RJ.

Pharmaceuticals (Basel). 2017 May 4;10(2). pii: E44. doi: 10.3390/ph10020044. Review.

15.

Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability.

Wang X, Li SH, Zhu L, Nian QG, Yuan S, Gao Q, Hu Z, Ye Q, Li XF, Xie DY, Shaw N, Wang J, Walter TS, Huiskonen JT, Fry EE, Qin CF, Stuart DI, Rao Z.

Nat Commun. 2017 Apr 26;8(1):14. doi: 10.1038/s41467-017-00024-6.

16.

Temperature-dependent folding allows stable dimerization of secretory and virus-associated E proteins of Dengue and Zika viruses in mammalian cells.

Slon Campos JL, Marchese S, Rana J, Mossenta M, Poggianella M, Bestagno M, Burrone OR.

Sci Rep. 2017 Apr 19;7(1):966. doi: 10.1038/s41598-017-01097-5.

17.

Current Status of Dengue Therapeutics Research and Development.

Low JG, Ooi EE, Vasudevan SG.

J Infect Dis. 2017 Mar 1;215(suppl_2):S96-S102. doi: 10.1093/infdis/jiw423. Review.

18.

Immune-mediated cytokine storm and its role in severe dengue.

Srikiatkhachorn A, Mathew A, Rothman AL.

Semin Immunopathol. 2017 Jul;39(5):563-574. doi: 10.1007/s00281-017-0625-1. Epub 2017 Apr 11. Review.

PMID:
28401256
19.

An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model.

Chahal JS, Fang T, Woodham AW, Khan OF, Ling J, Anderson DG, Ploegh HL.

Sci Rep. 2017 Mar 21;7(1):252. doi: 10.1038/s41598-017-00193-w.

20.

A human antibody against Zika virus crosslinks the E protein to prevent infection.

Hasan SS, Miller A, Sapparapu G, Fernandez E, Klose T, Long F, Fokine A, Porta JC, Jiang W, Diamond MS, Crowe JE Jr, Kuhn RJ, Rossmann MG.

Nat Commun. 2017 Mar 16;8:14722. doi: 10.1038/ncomms14722.

Supplemental Content

Support Center